Celeris Therapeutics ist ein Deep Learning Unternehmen, das mittels innovativer, computerbasierter Methoden genau diese Targets abbaubar macht und somit das Potenzial hat, Arzneimittel für Alzheimer und ähnliche Krankheiten zu entwickeln. Die technische Lösung von Celeris Therapeutics ist die Web-Applikation Celeris One. Potenzielle Nutzer dieser Applikation sind Pharma- und Biotech-Unternehmen mit Fokus auf Targeted Protein Degradation. Sie besteht aus 3 Modulen: Xanthos, Hephaistos und Hades.
We are a small private spin-off company from the Medical University of Graz, Austria. NGFI provides innovative products, services, support, and training for life science/medical researchers and biotech companies. We offer microscopic devices for research and special tools such as novel genetically encoded fluorescent probes as well as stable cell lines and research reagents in an affordable manner. Our main aim is to support scientists by providing products "from researchers for researchers".
Brain Implant Therapeutics (BIT) Pharma was founded in November 2015 by leaders from academia and industry. The company resides in Graz, Austria. BIT Pharma develops and commercializes technologies for site-specific drug delivery to the central nervous system (CNS), in particular the brain, exploiting tailored drug delivery systems.
Fresenius Kabi Austria, ist ein Tochterunternehmen des internationalen Gesundheitskonzerns Fresenius Kabi. Fresenius Kabi ist spezialisiert auf intravenös zu verabreichende generische Arzneimittel, Infusionstherapie und klinische Ernährung. Die Aktivitäten umfassen Entwicklung, Herstellung und Vertrieb von Produkten, die zur Verbesserung der Lebensqualität chronisch und kritisch kranker Patienten im Krankenhaus und im außerklinischen Bereich beitragen.
VALIDOGEN, formerly known as VTU Technology, is a leading Austrian contract research and development company. VALIDOGEN offers UNLOCK PICHIA - the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. Founded in 2008, the company emerged to a globally recognized player in the field of Pichia pastoris based protein expression. VALIDOGEN has established a broad range of tools and know-how for the generation of high-performance Pichia processes. Exclusive proprietary technologies and profound experience of the VALIDOGEN team lead to competitive production processes for a wide range of recombinant proteins. Headquartered in Raaba-Grambach, near Graz, Austria, VALIDOGEN is a private company and independent subsidiary of the KonValue Holding GmbH.
QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.